Last edition
News about "Pfizer MagnetisMM-32 Study"
Pfizer's ELREXFIO Meets Phase 3 Endpoint in Myeloma
Pfizer’s ELREXFIO has outperformed standard regimens and meets primary endpoint in phase 3 study in Relapsed or Refractory Multiple Myeloma (RRMM).
Pfizer MagnetisMM-32 Study | 28/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members